untitled design

Cyprus: Merck anti-coronavirus pill available today

His satisfaction for the actions that led to being the Cyprus “One of the first countries in the European Union to proceed with its purchase and distribution antiviral drug Molnupiravir (Lagevrio)” for coronavirus expressed earlier Monday the Minister of Health of Cyprus Michalis Hadjipandela.

“Our country now has the specific drug, which contributes to the treatment of the pandemic and protects patients at high risk of severe disease from Covid-19 disease,” said the minister in a press conference given by the ministry on the issue, while assuring “As the Ministry of Health, we are constantly on the lookout for new vaccines and new treatments against Covid-19 and are actively involved in all collaborations to ensure that new vaccines and medicines against Covid are delivered as soon as possible. -19 ».

Subsequently, the Deputy Director of Pharmaceutical Services of the Ministry, Dr. Elena Panayotopoulou, presented the data on Molnupiravir, describing the mechanism of action and its effectiveness and analyzing the groups for which its administration is recommended based on the risk factors for serious disease and explaining the prescription process.

Dr. Panagiotopoulou reported important information about taking, side effects and population groups for which there is a contraindication, and explained the system of reporting side effects “Yellow card», For careful and detailed reporting of these symptoms to the Pharmaceutical Services of the Ministry of Health.

Reduces the risk of serious illness or death, according to clinical studies

This was followed by a discussion with the representatives of the Media for answers to questions in relation to the pill of Merck.

Dr. Panagiotopoulou pointed out that Molnupiravir, although still in licensing process, has received recommendation from the European Medicines Agency in the context of emergency disposal, given the protection it has shown to offer through the clinical trials that have been conducted.

In particular, Molnupiravir has been shown to reduce the risk of serious illness or death in people with Covid-19 from 14.1% in placebo. 7,3% in people taking Molnupiravir, from a group 775 total number of participants.

You may also like

Get the latest

Stay Informed: Get the Latest Updates and Insights

 

Most popular